Estimated Mean and Total Inpatient Visit Costs (Healthcare Cost and Utilization Project, 2018) for Fungal Disease, United States
| Infection . | Mean Cost per Fungal Disease Visit . | Total Costa of Fungal Disease Visits . | ||
|---|---|---|---|---|
| Fungi as Primary Cause (95% CI) . | Any Fungal Diagnosis (95% CI) . | Fungi as Primary Cause (95% CI) . | Any Fungal Diagnosis (95% CI) . | |
| Aspergillosis | 66 105 (62 800–69 410) | 98 033 (93 131–102 934) | 163 940 796 (155 743 756–172 137 836) | 1 747 430 906 (1 660 059 361–1 834 802 452) |
| Invasive | 82 775 (78 636–86 914) | 108 811 (103 371–114 252) | 127 887 346 (121 492 979–134 281 714) | 955 906 163 (908 110 854–1 003 701 471) |
| Noninvasive | 31 362 (29 794–32 930) | 65 907 (62 611–69 202) | 14 426 614 (13 705 284–15 147 945) | 277 466 678 (263 593 344–291 340 012) |
| Candidiasis | 40 424 (38 403–42 445) | 57 158 (54 300–60 015) | 642 334 975 (610 218 226–674 451 724) | 26 125 565 468 (24 819 287 195–27 431 843 742) |
| Invasive | 84 978 (80 729–89 227) | 160 345 (152 328–168 363) | 414 691 141 (393 956 584–435 425 698) | 3 194 080 605 (3 034 376 575–3 353 784 636) |
| Noninvasive | 20 669 (19 636–21 703) | 53 685 (51 001–56 369) | 225 400 476 (214 130 452–236 670 500) | 21 300 382 453 (20 235 363 330–22 365 401 575) |
| Coccidioidomycosis | 53 839 (51 147–56 531) | 58 948 (56 001–61 896) | 121 945 200 (115 847 940–128 042 460) | 529 946 416 (503 449 095–556 443 736) |
| Cryptococcosis | 113 261 (107 598–118 924) | 97 925 (93 028–102 821) | 144 974 607 (137 725 877–152 223 338) | 479 830 280 (455 838 766–503 821 794) |
| Histoplasmosis | 46 565 (44 237–48 894) | 52 115 (49 509–54 720) | 34 924 097 (33 177 892–36 670 302) | 254 318 889 (241 602 945–267 034 833) |
| Mucormycosis | 169 260 (160 797–177 723) | 181 719 (172 633–190 805) | 51 624 441 (49 043 219–54 205 663) | 248 955 197 (236 507 437–261 402 957) |
| Pneumocystosis | 55 900 (53 105–58 695) | 70 632 (67 101–74 164) | 79 936 583 (75 939 754–83 933 412) | 686 899 945 (652 554 948–721 244 942) |
| Other | 47 663 (45 280–50 046) | 38 891 (36 947–40 836) | 203 997 272 (193 797 408–214 197 135) | 5 675 239 705 (5 391 477 720–5 959 001 690) |
| Unspecified mycoses | 31 049 (29 497–32 602) | 122 560 (116 432–128 688) | 17 387 616 (16 518 235–18 256 997) | 1 904 577 381 (1 809 348 512–1 999 806 250) |
| Total cost | 49 731 (47 245–52 218) | 55 418 (52 647–58 189) | 1 461 065 586 (1 388 012 307–1 534 118 865) | 37 652 764 187 (35 770 125 978–39 535 402 397) |
| Infection . | Mean Cost per Fungal Disease Visit . | Total Costa of Fungal Disease Visits . | ||
|---|---|---|---|---|
| Fungi as Primary Cause (95% CI) . | Any Fungal Diagnosis (95% CI) . | Fungi as Primary Cause (95% CI) . | Any Fungal Diagnosis (95% CI) . | |
| Aspergillosis | 66 105 (62 800–69 410) | 98 033 (93 131–102 934) | 163 940 796 (155 743 756–172 137 836) | 1 747 430 906 (1 660 059 361–1 834 802 452) |
| Invasive | 82 775 (78 636–86 914) | 108 811 (103 371–114 252) | 127 887 346 (121 492 979–134 281 714) | 955 906 163 (908 110 854–1 003 701 471) |
| Noninvasive | 31 362 (29 794–32 930) | 65 907 (62 611–69 202) | 14 426 614 (13 705 284–15 147 945) | 277 466 678 (263 593 344–291 340 012) |
| Candidiasis | 40 424 (38 403–42 445) | 57 158 (54 300–60 015) | 642 334 975 (610 218 226–674 451 724) | 26 125 565 468 (24 819 287 195–27 431 843 742) |
| Invasive | 84 978 (80 729–89 227) | 160 345 (152 328–168 363) | 414 691 141 (393 956 584–435 425 698) | 3 194 080 605 (3 034 376 575–3 353 784 636) |
| Noninvasive | 20 669 (19 636–21 703) | 53 685 (51 001–56 369) | 225 400 476 (214 130 452–236 670 500) | 21 300 382 453 (20 235 363 330–22 365 401 575) |
| Coccidioidomycosis | 53 839 (51 147–56 531) | 58 948 (56 001–61 896) | 121 945 200 (115 847 940–128 042 460) | 529 946 416 (503 449 095–556 443 736) |
| Cryptococcosis | 113 261 (107 598–118 924) | 97 925 (93 028–102 821) | 144 974 607 (137 725 877–152 223 338) | 479 830 280 (455 838 766–503 821 794) |
| Histoplasmosis | 46 565 (44 237–48 894) | 52 115 (49 509–54 720) | 34 924 097 (33 177 892–36 670 302) | 254 318 889 (241 602 945–267 034 833) |
| Mucormycosis | 169 260 (160 797–177 723) | 181 719 (172 633–190 805) | 51 624 441 (49 043 219–54 205 663) | 248 955 197 (236 507 437–261 402 957) |
| Pneumocystosis | 55 900 (53 105–58 695) | 70 632 (67 101–74 164) | 79 936 583 (75 939 754–83 933 412) | 686 899 945 (652 554 948–721 244 942) |
| Other | 47 663 (45 280–50 046) | 38 891 (36 947–40 836) | 203 997 272 (193 797 408–214 197 135) | 5 675 239 705 (5 391 477 720–5 959 001 690) |
| Unspecified mycoses | 31 049 (29 497–32 602) | 122 560 (116 432–128 688) | 17 387 616 (16 518 235–18 256 997) | 1 904 577 381 (1 809 348 512–1 999 806 250) |
| Total cost | 49 731 (47 245–52 218) | 55 418 (52 647–58 189) | 1 461 065 586 (1 388 012 307–1 534 118 865) | 37 652 764 187 (35 770 125 978–39 535 402 397) |
Costs are presented in 2018 United States dollars.
Abbreviation: CI, confidence interval.
Total costs are summed by pathogen without duplication of values included in invasive/noninvasive types.
Estimated Mean and Total Inpatient Visit Costs (Healthcare Cost and Utilization Project, 2018) for Fungal Disease, United States
| Infection . | Mean Cost per Fungal Disease Visit . | Total Costa of Fungal Disease Visits . | ||
|---|---|---|---|---|
| Fungi as Primary Cause (95% CI) . | Any Fungal Diagnosis (95% CI) . | Fungi as Primary Cause (95% CI) . | Any Fungal Diagnosis (95% CI) . | |
| Aspergillosis | 66 105 (62 800–69 410) | 98 033 (93 131–102 934) | 163 940 796 (155 743 756–172 137 836) | 1 747 430 906 (1 660 059 361–1 834 802 452) |
| Invasive | 82 775 (78 636–86 914) | 108 811 (103 371–114 252) | 127 887 346 (121 492 979–134 281 714) | 955 906 163 (908 110 854–1 003 701 471) |
| Noninvasive | 31 362 (29 794–32 930) | 65 907 (62 611–69 202) | 14 426 614 (13 705 284–15 147 945) | 277 466 678 (263 593 344–291 340 012) |
| Candidiasis | 40 424 (38 403–42 445) | 57 158 (54 300–60 015) | 642 334 975 (610 218 226–674 451 724) | 26 125 565 468 (24 819 287 195–27 431 843 742) |
| Invasive | 84 978 (80 729–89 227) | 160 345 (152 328–168 363) | 414 691 141 (393 956 584–435 425 698) | 3 194 080 605 (3 034 376 575–3 353 784 636) |
| Noninvasive | 20 669 (19 636–21 703) | 53 685 (51 001–56 369) | 225 400 476 (214 130 452–236 670 500) | 21 300 382 453 (20 235 363 330–22 365 401 575) |
| Coccidioidomycosis | 53 839 (51 147–56 531) | 58 948 (56 001–61 896) | 121 945 200 (115 847 940–128 042 460) | 529 946 416 (503 449 095–556 443 736) |
| Cryptococcosis | 113 261 (107 598–118 924) | 97 925 (93 028–102 821) | 144 974 607 (137 725 877–152 223 338) | 479 830 280 (455 838 766–503 821 794) |
| Histoplasmosis | 46 565 (44 237–48 894) | 52 115 (49 509–54 720) | 34 924 097 (33 177 892–36 670 302) | 254 318 889 (241 602 945–267 034 833) |
| Mucormycosis | 169 260 (160 797–177 723) | 181 719 (172 633–190 805) | 51 624 441 (49 043 219–54 205 663) | 248 955 197 (236 507 437–261 402 957) |
| Pneumocystosis | 55 900 (53 105–58 695) | 70 632 (67 101–74 164) | 79 936 583 (75 939 754–83 933 412) | 686 899 945 (652 554 948–721 244 942) |
| Other | 47 663 (45 280–50 046) | 38 891 (36 947–40 836) | 203 997 272 (193 797 408–214 197 135) | 5 675 239 705 (5 391 477 720–5 959 001 690) |
| Unspecified mycoses | 31 049 (29 497–32 602) | 122 560 (116 432–128 688) | 17 387 616 (16 518 235–18 256 997) | 1 904 577 381 (1 809 348 512–1 999 806 250) |
| Total cost | 49 731 (47 245–52 218) | 55 418 (52 647–58 189) | 1 461 065 586 (1 388 012 307–1 534 118 865) | 37 652 764 187 (35 770 125 978–39 535 402 397) |
| Infection . | Mean Cost per Fungal Disease Visit . | Total Costa of Fungal Disease Visits . | ||
|---|---|---|---|---|
| Fungi as Primary Cause (95% CI) . | Any Fungal Diagnosis (95% CI) . | Fungi as Primary Cause (95% CI) . | Any Fungal Diagnosis (95% CI) . | |
| Aspergillosis | 66 105 (62 800–69 410) | 98 033 (93 131–102 934) | 163 940 796 (155 743 756–172 137 836) | 1 747 430 906 (1 660 059 361–1 834 802 452) |
| Invasive | 82 775 (78 636–86 914) | 108 811 (103 371–114 252) | 127 887 346 (121 492 979–134 281 714) | 955 906 163 (908 110 854–1 003 701 471) |
| Noninvasive | 31 362 (29 794–32 930) | 65 907 (62 611–69 202) | 14 426 614 (13 705 284–15 147 945) | 277 466 678 (263 593 344–291 340 012) |
| Candidiasis | 40 424 (38 403–42 445) | 57 158 (54 300–60 015) | 642 334 975 (610 218 226–674 451 724) | 26 125 565 468 (24 819 287 195–27 431 843 742) |
| Invasive | 84 978 (80 729–89 227) | 160 345 (152 328–168 363) | 414 691 141 (393 956 584–435 425 698) | 3 194 080 605 (3 034 376 575–3 353 784 636) |
| Noninvasive | 20 669 (19 636–21 703) | 53 685 (51 001–56 369) | 225 400 476 (214 130 452–236 670 500) | 21 300 382 453 (20 235 363 330–22 365 401 575) |
| Coccidioidomycosis | 53 839 (51 147–56 531) | 58 948 (56 001–61 896) | 121 945 200 (115 847 940–128 042 460) | 529 946 416 (503 449 095–556 443 736) |
| Cryptococcosis | 113 261 (107 598–118 924) | 97 925 (93 028–102 821) | 144 974 607 (137 725 877–152 223 338) | 479 830 280 (455 838 766–503 821 794) |
| Histoplasmosis | 46 565 (44 237–48 894) | 52 115 (49 509–54 720) | 34 924 097 (33 177 892–36 670 302) | 254 318 889 (241 602 945–267 034 833) |
| Mucormycosis | 169 260 (160 797–177 723) | 181 719 (172 633–190 805) | 51 624 441 (49 043 219–54 205 663) | 248 955 197 (236 507 437–261 402 957) |
| Pneumocystosis | 55 900 (53 105–58 695) | 70 632 (67 101–74 164) | 79 936 583 (75 939 754–83 933 412) | 686 899 945 (652 554 948–721 244 942) |
| Other | 47 663 (45 280–50 046) | 38 891 (36 947–40 836) | 203 997 272 (193 797 408–214 197 135) | 5 675 239 705 (5 391 477 720–5 959 001 690) |
| Unspecified mycoses | 31 049 (29 497–32 602) | 122 560 (116 432–128 688) | 17 387 616 (16 518 235–18 256 997) | 1 904 577 381 (1 809 348 512–1 999 806 250) |
| Total cost | 49 731 (47 245–52 218) | 55 418 (52 647–58 189) | 1 461 065 586 (1 388 012 307–1 534 118 865) | 37 652 764 187 (35 770 125 978–39 535 402 397) |
Costs are presented in 2018 United States dollars.
Abbreviation: CI, confidence interval.
Total costs are summed by pathogen without duplication of values included in invasive/noninvasive types.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
